As Malvinder Singh steers Ranbaxy into 2008, he’s a happy man
As the largest player in India’s pharmaceutical industry, Ranbaxy’s meteoric rise can be attributed to lot of factors. But one, which simply can’t be ignored, is the highly aggressive streak in Malvinder Singh’s (CEO & MD, Ranbaxy Laboratories Ltd.) personality. Under his aggressive guidance, the pharma major is all set to unlock its future potential in 2008. This year, he not only wants to make key acquisitions in emerging markets; but also on the cards is the bid to start launching First-to-File (FTF) products.
No doubt, Indian pharmaceutical companies have been going through a rough patch for quite some time now. Even Ranbaxy has seen its worst, with rising pricing pressures in the generic industry. However, industry experts say that the worst will be over in 2008. Going forward, “Ranbaxy is all for recovery, on the back of various initiatives taken, among them, enhancing its presence in the less penetrated regulated markets and having a robust product-pipeline,” prophesies S. Nangra of Angel Broking.
Over the past few years, Malvinder has managed to create a more balanced business model for Ranbaxy with near-equal emphasis on developed and emerging markets – all set to deliver results at a time when the world’s largest pharma market, the US, is going through severe pricing pressures. Moreover, he took a conscious decision to increase Ranbaxy’s focus on emerging markets a few years back, and has advantageously positioned itself ahead of others. “We will continue to focus on expanding operations in emerging markets like Romania, Brazil, Russia, China, South Africa, Central & Eastern European nations,” he told this magazine. No doubt, these markets which are primarily branded ‘generics’ have relatively higher profit margins, offering sustainable earnings.
While Ranbaxy moves into 2008, Malvinder expects a surge in the demand for generic medicines prompted by a large number of patent expiries across the globe. According to industry experts, drugs worth $60–70 billion are estimated go off patent in the next few years. And Malvinder is all set to capitalise on this huge opportunity, as Ranbaxy has now gained a strong foothold in prolific markets like the US, Europe & other developed countries. “We will look at acquisition opportunities in the US, Europe, India and other emerging markets and will consider target companies based on the value and the synergies that can be unlocked from such a deal,” he told this magazine. Moreover, with 18 FTF products (significant amongst them being Valtrex, Lipitor, Flomax) having a market size of $26 billion, the company is all set to rake in the moolah. Malvinder plans to launch these FTF products starting 2008, which offer a major commercial upside to Ranbaxy’s organic growth plans.
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2008
As the largest player in India’s pharmaceutical industry, Ranbaxy’s meteoric rise can be attributed to lot of factors. But one, which simply can’t be ignored, is the highly aggressive streak in Malvinder Singh’s (CEO & MD, Ranbaxy Laboratories Ltd.) personality. Under his aggressive guidance, the pharma major is all set to unlock its future potential in 2008. This year, he not only wants to make key acquisitions in emerging markets; but also on the cards is the bid to start launching First-to-File (FTF) products.
No doubt, Indian pharmaceutical companies have been going through a rough patch for quite some time now. Even Ranbaxy has seen its worst, with rising pricing pressures in the generic industry. However, industry experts say that the worst will be over in 2008. Going forward, “Ranbaxy is all for recovery, on the back of various initiatives taken, among them, enhancing its presence in the less penetrated regulated markets and having a robust product-pipeline,” prophesies S. Nangra of Angel Broking.
Over the past few years, Malvinder has managed to create a more balanced business model for Ranbaxy with near-equal emphasis on developed and emerging markets – all set to deliver results at a time when the world’s largest pharma market, the US, is going through severe pricing pressures. Moreover, he took a conscious decision to increase Ranbaxy’s focus on emerging markets a few years back, and has advantageously positioned itself ahead of others. “We will continue to focus on expanding operations in emerging markets like Romania, Brazil, Russia, China, South Africa, Central & Eastern European nations,” he told this magazine. No doubt, these markets which are primarily branded ‘generics’ have relatively higher profit margins, offering sustainable earnings.
While Ranbaxy moves into 2008, Malvinder expects a surge in the demand for generic medicines prompted by a large number of patent expiries across the globe. According to industry experts, drugs worth $60–70 billion are estimated go off patent in the next few years. And Malvinder is all set to capitalise on this huge opportunity, as Ranbaxy has now gained a strong foothold in prolific markets like the US, Europe & other developed countries. “We will look at acquisition opportunities in the US, Europe, India and other emerging markets and will consider target companies based on the value and the synergies that can be unlocked from such a deal,” he told this magazine. Moreover, with 18 FTF products (significant amongst them being Valtrex, Lipitor, Flomax) having a market size of $26 billion, the company is all set to rake in the moolah. Malvinder plans to launch these FTF products starting 2008, which offer a major commercial upside to Ranbaxy’s organic growth plans.
For Complete IIPM Article, Click on IIPM Article
Source : IIPM Editorial, 2008
An IIPM and Professor Arindam Chaudhuri (Renowned Management Guru and Economist) Initiative
Read these article :-
B-schooled in India, Placed Abroad (Print Version)
IIPM in Financial times (Print Version)
IIPM makes business education truly global
The Indian Institute of Planning and Management (IIPM)
IIPM Campus
4 comments:
The IIPM Think Tank, an independent, India-centric research body, is inspired by Dr. MK Chaudhuri's
IIPM in the New Delhi, also known as The Indian Institute of Planning and Management is the best known planning and entrepreneurship program institute
IIPM placements in the New Delhi and across India are the world best placements.
iipm campus placements are the best
Post a Comment